INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 285 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $299,726 | +8.0% | 5,754 | +31.3% | 0.00% | – |
| Q2 2023 | $277,405 | -13.0% | 4,381 | -52.9% | 0.00% | -100.0% |
| Q4 2019 | $319,000 | +20.4% | 9,300 | -54.5% | 0.00% | 0.0% |
| Q2 2019 | $265,000 | +6.4% | 20,425 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $249,000 | +9.2% | 20,425 | +2.1% | 0.00% | 0.0% |
| Q4 2018 | $228,000 | +1972.7% | 20,000 | +2122.2% | 0.00% | – |
| Q2 2017 | $11,000 | -26.7% | 900 | 0.0% | 0.00% | – |
| Q1 2017 | $15,000 | +1400.0% | 900 | +1536.4% | 0.00% | – |
| Q4 2016 | $1,000 | -50.0% | 55 | -57.7% | 0.00% | – |
| Q3 2016 | $2,000 | – | 130 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 424,500 | $13,499,000 | 5.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $6,360,000 | 3.70% |
| Asymmetry Capital Management, L.P. | 130,654 | $4,155,000 | 1.90% |
| Altium Capital Management LP | 153,348 | $4,876,000 | 1.82% |
| Sofinnova Investments, Inc. | 848,162 | $26,972,000 | 1.61% |
| Bellevue Group AG | 3,659,919 | $116,386,000 | 1.33% |
| Eversept Partners, LP | 356,235 | $11,328,273 | 1.33% |
| Rhenman & Partners Asset Management AB | 500,000 | $15,900,000 | 1.30% |
| GENERAL AMERICAN INVESTORS CO INC | 347,497 | $11,050,000 | 1.09% |
| WASATCH ADVISORS LP | 6,333,900 | $201,418,000 | 0.99% |